Skip to main content
Toggle navigation
Login
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
G
Gaitonde, Puneet
Pfizer Inc.
(
S-043
)
Near Real-Time Apixaban Clinical Dose Decision-Making in Treating a Neonatal Venous Thromboembolism Population Using the InsightRX Nova™ Platform
Puneet Gaitonde
Favorite
Garhyan, Arnay
Park Tudor High School
(
M-112
)
Development and Evaluation of PKPD Models for QT Interval Changes Post-Moxifloxacin Dosing in Non-Human Primates
Arnay Garhyan
Favorite
Gaurav, Mitali
Simulations Plus
(
M-103
)
Population Pharmacokinetic Analysis of QRL-201 in Plasma and CSF in Patients With Amyotrophic Lateral Sclerosis From A First-in-Human Phase 1 Multiple Ascending Dose Escalation Study
Mitali Gaurav
Favorite
Ghusinga, Khem Raj
AstraZeneca
(
S-067
)
Moment closure for uncertainty propagation in QSP models
Khem Raj Ghusinga
Favorite
Gibson, Elizabeth
Bristol Myers Squibb
(
S-082
)
Model-Based Approach to Support Nivolumab Subcutaneous Dose Selection in Pediatric Patients (12 to <18 Years) in Multiple Solid Tumor Indications
Elizabeth Gibson
Favorite
GONG, CHANG
AstraZeneca
(
S-087
)
A Quantitative Systems Pharmacology (QSP) Model Platform to Study the Impact of Intra-tumoral Heterogeneity on Antibody-Drug Conjugate (ADC) Treatment Efficacy
CHANG GONG
Favorite
Goo, Sungwoo
Institute of Drug Research & Development, Chungnam National University
(
S-013
)
Proteosis-Targeting Chimera Efficacy Prediction Using a Deep-Learning–QSP Model
Sungwoo Goo
Favorite
(
S-014
)
Survival Modeling of Dementia Risk Using Metabolic Syndrome-Related Genetic Variants
Sungwoo Goo
Favorite
Goryacheva, Ekaterina
InSysBio UK, Edinburgh, UK
(
S-074
)
From Data to Parameters: FIVEDB as a Tool for Efficient QSP Model Calibration
Ekaterina Goryacheva
Favorite
Gosselin, Nathalie
Certara
(
T-080
)
Population Pharmacokinetic/Pharmacodynamic Modeling and Analysis of Tetrahydrobiopterin and Blood Phenylalanine Response in Adult and Pediatric Patients with Phenylketonuria During Sepiapterin Treatment
Nathalie Gosselin
Favorite
Goteti, Kosalaram
Seaport Therapeutics
(
M-047
)
Prediction of human pharmacokinetic profiles of Glyph(TM) platform prodrugs using animal and human data via a semi-mechanistic pharmacokinetic model
Kosalaram Goteti
Favorite
Guan, Xiao-duo
Clinical Pharmacology, Development China, Pfizer Inc., Beijing, China
(
S-055
)
Population Pharmacokinetics of Elranatamab in Chinese Patients with Relapsed or Refractory Multiple Myeloma using PRIOR Approach
Xiao-duo Guan
Favorite
Gunputh, Narshini
Rochester Institute of Technology
(
M-063
)
Quantitative Model of the Ocular Immune Response to Seasonal Allergic Conjunctivitis
Narshini Gunputh
Favorite
Guo, Yizhen
Bristol Myers Squibb
(
M-056
)
Time-to-event exposure-response based clinical utility index framework to facilitate optimal dose selection
Yizhen Guo
Favorite
GUPTA, PARIDHI
Bristol Myers Squibb
(
M-007
)
Intravenous Immunoglobulin G (IVIG)-Monoclonal Antibody (mAb) Drug Interactions: Time for Model-Informed Clinical Guidance?
PARIDHI GUPTA
Favorite
(
M-008
)
Exposure-Response Analysis of Efficacy and Safety for Nivolumab + Relatlimab Fixed-dose Combination (FDC) to Support Dose Justification in Patients with Unresectable or Metastatic Melanoma
PARIDHI GUPTA
Favorite
